Top 5 Electric Utility Companies To Buy For 2015: Pacira Pharmaceuticals Inc.(PCRX)
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, commercialization, and manufacture of pharmaceutical products for use in hospitals and ambulatory surgery centers. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Its product portfolio includes EXPAREL, a long-acting non-opioid postsurgical analgesic for postsurgical pain management; DepoCyt for the treatment of lymphomatous meningitis, a cancer of the immune system; DepoDur for controlling post operative pain; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis oncology. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.Advisors' Opinion:
- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Monday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Nordion (NYSE: NDZ) and Pacira Pharmaceuticals (NASDAQ: PCRX). Utilities sector rose by just 0.19 percent in the US market today.
- [By STOCKPICKR]
Pacira Pharmaceuticals (PCRX) is an emerging specialty pharmaceutical company engaged in development, commercialization and manufacture of proprietary pharmaceutical products for use in hospitals and ambulatory surgery centers. This stock closed up 12.5% at $55.93 in Monday's trading session.
Monday's Volume: 944,000
Three-Month Average Volume: 517,152
Volume % Change: 80%
From a technical perspective, PCRX exploded higher here back above its 50-day moving average of $52.50 with above-average volume. This stock recently formed a double bot! tom chart pattern at $46.55 to $47.21. Since forming that bottom, shares of PCRX have started to rip higher and move within range of triggering a major breakout trade. That trade will hit if PCRX manages to take out Monday's intraday high of $56 to its 52-week high at $56.94 with high volume.
Traders should now look for long-biased trades in PCRX as long as it's trending above its 50-day at $52.20 and then once it sustains a move or close above those breakout levels with volume that's near or above 517,152 shares. If that breakout hits soon, then PCRX will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $60 to $63.
A.M. Castel (CAS) is a specialty metals and plastics distribution company. Its core products include nickel alloys, aluminum, stainless steel and carbon in various forms, such as plate, bars, tubing and coil. This stock closed up 9% at $14.88 in Monday's trading session.
Monday's Volume: 487,000
Three-Month Average Volume: 156,083
Volume % Change: 204%
From a technical perspective, CAS gapped sharply higher here back above its 50-day moving average of $14.27 and into breakout territory above some near-term overhead resistance at $14.37 with strong upside volume. This move pushed shares of CAS out of its downtre
- [By Lisa Levin]
Pacira Pharmaceuticals (NASDAQ: PCRX) shares moved up 6.48% to $69.69. The volume of Pacira Pharmaceuticals shares traded was 350% higher than normal. Pacira Pharmaceuticals priced its public offering of 1,600,000 shares at $64.00 per share.
source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-electric-utility-companies-to-buy-for-2015-2.html